Unknown

Dataset Information

0

Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control.


ABSTRACT: The current enhanced permeability and retention (EPR)-based approved nanomedicines have had little impact in terms of prolongation of overall survival in patients with cancer. For example, the two Phase III trials comparing Doxil(®), the first nanomedicine approved by the US Food and Drug Administration, with free doxorubicin did not find an actual translation of the EPR effect into a statistically significant increase in overall survival but did show less cardiotoxicity. In the current work, we used a two-factor factorial experimental design with intraperitoneal versus intravenous delivery and nanomedicine versus free drug as factors to test our hypothesis that regional (intraperitoneal) delivery of nanomedicine may better increase survival when compared with systemic delivery. In this study, we demonstrate that bypassing, rather than exploiting, the EPR effect via intraperitoneal delivery of nanomedicine harboring a sustained-release function demonstrates dual pharmacokinetic advantages, producing more efficient tumor control and suppressing the expression of stemness markers, epithelial-mesenchymal transition, angiogenesis signals, and multidrug resistance in the tumor microenvironment. Metastases to vital organs (eg, lung, liver, and lymphatic system) are also better controlled by intraperitoneal delivery of nanomedicine than by standard systemic delivery of the corresponding free drug. Moreover, the intraperitoneal delivery of nanomedicine has the potential to replace hyperthermic intraperitoneal chemotherapy because it shows equal efficacy and lower toxicity. In terms of efficacy, exploiting the EPR effect may not be the best approach for developing a nanomedicine. Because intraperitoneal chemotherapy is a type of regional chemotherapy, the pharmaceutical industry might consider the regional delivery of nanomedicine as a valid alternative pathway to develop their nanomedicine(s) with the goal of better tumor control in the future.

SUBMITTER: Shen YA 

PROVIDER: S-EPMC4386769 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control.

Shen Yao An YA   Shyu Ing Luen IL   Lu Maggie M   He Chun Lin CL   Hsu Yen Mei YM   Liang Hsiang Fa HF   Liu Chih Peng CP   Liu Ren Shyan RS   Shen Biing Jiun BJ   Wei Yau Huei YH   Chuang Chi Mu CM  

International journal of nanomedicine 20150330


The current enhanced permeability and retention (EPR)-based approved nanomedicines have had little impact in terms of prolongation of overall survival in patients with cancer. For example, the two Phase III trials comparing Doxil(®), the first nanomedicine approved by the US Food and Drug Administration, with free doxorubicin did not find an actual translation of the EPR effect into a statistically significant increase in overall survival but did show less cardiotoxicity. In the current work, we  ...[more]

Similar Datasets

| S-EPMC6857058 | biostudies-literature
| S-EPMC3913470 | biostudies-literature
| S-EPMC3718995 | biostudies-literature
2021-11-23 | GSE179704 | GEO
| S-EPMC9807901 | biostudies-literature
2021-11-23 | GSE179702 | GEO
2021-11-23 | GSE179697 | GEO
| S-EPMC5471179 | biostudies-other
| S-EPMC5483847 | biostudies-other
| S-EPMC5744178 | biostudies-literature